Crinetics Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2023-12-11

Reporting Person: Betz Stephen F. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-11	Common Stock	S	3000	$32.87	Disposed	82298	Direct

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.

F2: The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $32.87 per share. The range of sales prices on the transaction date was $32.84 to $33.50 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.